Published • loading... • Updated
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ...
Investors may seek compensation on a contingency-fee basis after allegations that Power Solutions misled the market about data-center demand and manufacturing capacity.
- On Tuesday, May 5, 2026, The Rosen Law Firm announced a class action lawsuit for Nektar Therapeutics investors who purchased securities between February 26, 2025 and December 15, 2025, with today marking the final deadline to seek lead plaintiff status.
- The lawsuit alleges that enrollment in Nektar's REZOLVE-AA trial failed to follow applicable instructions and protocol standards, likely undermining trial results and overstating the trial's integrity when investors relied on public statements.
- Rosen Law has ranked in the top 4 firms for securities class action settlements annually since 2013 and secured over $438 million for investors in 2019 alone, demonstrating capacity for complex litigation.
- Eligible investors may pursue compensation through a contingency fee arrangement without out-of-pocket costs, or alternatively remain absent class members and do nothing at this time.
- Investors intending to serve as lead plaintiff must move the Court by today's deadline, as the firm continues representing shareholders globally in complex securities litigation and derivative actions.
Insights by Ground AI
27 Articles
27 Articles
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the ...
LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS ) for violations of §§10(b)…
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ...
LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA ) violations of §§10(b) and…
·Nebraska, United States
Read Full Article
Coverage Details
Total News Sources27
Leaning Left6Leaning Right2Center14Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 27%
C 64%
Factuality
To view factuality data please Upgrade to Premium
